World Trade Center responders with prostate cancer showed signs that inflammation was activated in the prostate after exposure to dust from the World Trade Center site, possibly causing chronic inflammation that contributed to their cancer, according to a study by Mount Sinai researchers in Molecular Cancer Research in June.
There were more than 16.9 million Americans with a history of cancer on Jan. 1, 2019. The number is projected to reach more than 22.1 million by 2030 based on the growth and aging of the population alone, according to estimates from Cancer Treatment and Survivorship Statistics, 2019.
Researchers at the USC Norris Comprehensive Cancer Center found identifying a metastatic colorectal cancer patient's Consensus Molecular Subtype could help oncologists determine the most effective course of treatment. CMS also had prognostic value, meaning each subgroup was indicative of a patient's overall survival, regardless of therapy.
Study suggests higher triple-negative breast cancer incidence among black women is not generalizable
A new study found substantial variation in the prevalence of triple-negative breast cancer among black women with breast cancer by birthplace in the U.S.
Racial disparities in timely cancer treatment disappeared in states that expanded Medicaid under the Affordable Care Act, according to an analysis of over 30,000 health records led by researchers at Yale Cancer Center. The findings were presented at the American Society of Clinical Oncology 2019 annual meeting.
Novartis announced results from the COMBI-d and COMBI-v clinical trials, concluding first-line treatment with Tafinlar (dabrafenib) and Mekinist (trametinib) offers both overall and progression-free long-term survival benefits to patients with unresectable or metastatic BRAF-mutation positive melanoma.
Genentech announced results from the pivotal phase III CLL14 study in previously untreated chronic lymphocytic leukemia showing Venclexta (venetoclax) plus Gazyva (obinutuzumab) met its primary endpoint of investigator-assessed progression-free survival.
The results of a study led by physicians at Fred Hutchinson Cancer Research Center showed patients living with HIV and one of a variety of potentially deadly cancers could be safely treated with the immunotherapy drug pembrolizumab, Keytruda.
Bristol-Myers Squibb Co. announced first results from the Opdivo (nivolumab) plus Yervoy (ipilimumab) cohort of the phase I/II CheckMate-040 study, evaluating the immuno-oncology combination in patients with advanced hepatocellular carcinoma previously treated with sorafenib.
Results of a phase II clinical trial conducted at MD Anderson Cancer Center revealed combination targeted therapy, consisting of rituximab, lenalidomide, and ibrutinib, had an 84.6% overall response rate and 38.5% complete response rate when given prior to any chemotherapy for newly diagnosed patients with a specific type of diffuse large B-cell lymphoma.
